CD80,CD86和ICAM-1在急性白血病细胞上的表达及意义

Expressions and significance of CD80,CD86 and ICAM-1 on acute leukemic cells

目的通过流式细胞术检测初诊患者急性白血病细胞上共刺激分子CD80、CD86以及黏附分子ICAM-1的表达,以了解其表达规律。方法通过流式细胞仪检测60例初治急性白血患者白血病细胞上CD80、CD86和ICAM-1的表达率;男37例,女23例,年龄2～85岁,中位年龄28岁;其中ALL20例,AML40例(M16例、M27例、M37例、M415例、M55例)。结果ALL组中的CD86的表达为(32.880±6.665)%,显著高于正常对照(P<0.01),而CD80与正常BM对照比较无统计学意义;CD80、CD86在AML(M1、M2和M3)细胞上的表达分别为(0.766±0.187)%、(27.210±7.581)%,均显著高于相应的正常骨髓对照(P<0.01);在AML(M4和M5)细胞上CD80、CD86的表达与正常对照比较均无统计学意义。ICAM-1在ALL组中的表达与正常BM对照比较无统计学意义;在AML(M1、M2和M3)细胞上(63.820±7.484)%,显著高于相应的正常骨髓对照(P<0.01);而AML(M4和M5)细胞上表达为(50.590±7.092)%,显著低于相应的正常骨髓对照(P<0.01)。结论CD80、CD86和ICAM-1在初治ALL和AML白血病细胞上的表达呈一定变异性,CD86在ALL上呈高表达,CD80、CD86和ICAM-1在AML(M1、M2和M3)上均呈高表达,而ICAM-1在AML(M4和M5)上均呈低表达。

Objective To explore the variation pattern for CD80, CD86 and ICAM- 1 expressions on acute leukemic cells by flow cytometry. Methods Detection of the CD80, CD86 and ICAM-1 expressions by flow cytometric analysis on the acute leukemic cells from 60 newly treated patients. There were 37 males and 23 females. The median age was 28 years old （range： 2 to 85）. 20 cases were acute lymphoblastic leukemia （ALL） and 40 cases acute myeloid leukemia （AML）[consisting of MI（6）, M2（7）, M3（7）, M4（15） and M5（5）]. Results The expression of CD86 in ALL group, （32.880 ± 6.665）%, was significantly higher than that in normal control （P 〈 0.01）, CD80 expression showed no difference with normal control. The expressions of CD80 and CD86 on AML （M1, M2 and M3） cells were （0.766 ± 0.187）% and （27.210 ± 7.581）% respectively, both were significantly higher than that in normal control （P 〈 0.01）, but those on the AML （M4 and M5） cells had no difference with normal control. The expressions of ICAM-1 on AML （M1, M2 and M3） cells were （63.820 ± 7.484）% higher than that of control （P 〈 0.01）, but that was （50.590± 7.092）% on AML （M4 and M5） cells significantly lower than that of control （P 〈 0.01）, there is no difference of ICAM-1 expression between ALL group and normal control. Conclusions The expressions of CD80, CD86 and ICAM-1 on ALL and AML cells from newly diagnosed patients were variable. CD86 on ALL cells was high-expressing and CD80, CD86 together with ICAM-1 were high-expressing on AML （M1, M2 and M3） cells, whereas the ICAM-1 on the AML （M4 and M5） cells was low-expressing.